JERSEY CITY, N.J. , June 21, 2024 /PRNewswire/ -- InsightAce Analytic Pvt.
Ltd. announces the release of a market assessment report on the " Global Weight Loss Drugs Market - (By Drug Type (Prescription and Over-the-counter), By Product (Wegovy, Ozempic, Saxenda, Zepbound, Mounjaro and Others)), By Distribution Channel, By Region, Trends, Industry Competition Analysis, Revenue and Forecast To 2031." According to the latest research by InsightAce Analytic, the Global Weight Loss Drugs Market is valued at US$ 26.
3 Bn in 2023 , and it is expected to reach US$ 108.9 Bn by 2031 , with a CAGR of 19.7% during the forecast period of 2024-2031.
Download Free Sample Report Pages: https://www.insightaceanalytic.com/request-sample/2526 Weight loss drugs work through various mechanisms in the body to promote weight loss, such as reducing appetite, increasing feelings of fullness, decreasing absorption of nutrients, or increasing calorie expenditure.
The weight loss drugs market is propelled by the escalating global obesity crisis and increasing societal emphasis on health and wellness. As obesity rates surge worldwide, there is a heightened demand for effective weight management solutions. Concurrently, a cultural shift towards prioritizing health and fitness encourages individuals to seek tools to achieve and maintain a healthy weight.
These intertwined factors create a robust market for weight loss drugs, motivating pharmaceutical companies to innovate and develop new treatments to addr.